Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsHiddo J.L. Heerspink, Tom Greene, Hocine Tighiouart et al.|The Lancet Diabetes & Endocrinology|2019Cited by 372
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Manuel Praga et al.|The Lancet|2023Cited by 264
European consensus statement on the terminology used in the management of lupus glomerulonephritisCaroline Gordon, G. R. V. Hughes, David Jayne et al.|Lupus|2009Cited by 150
Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.Jeffrey Laurence, Santiago Rodrı́guez de Córdoba, Hermann Haller et al.|PubMed|2016Cited by 89
Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytesJosé Alberto Navarro‐García, Gema Ruiz‐Hurtado, Carmen Delgado et al.|Nephrology Dialysis Transplantation|2018Cited by 52